Teva Pharmaceutical Industries Limited (TEVA)
NYSE (ADR) / TASE · Tel Aviv, Israel · Founded 1901 · CEO Richard Francis
Valuation summary
$19.01 fair value versus $38.54 in the market, a difference of -50.7%. Rated Sell.
| Fair value per share | $19.01 |
| Current share price | $38.54 |
| Upside / downside | -50.7% |
| Bear case | $8.97 |
| Bull case | $33.36 |
| Discount rate (WACC) | 9.4% |
| Terminal growth | 2.00% |
| Market capitalisation | $45B |
| EV / Sales | 3.4x |
About Teva Pharmaceutical Industries Limited
Founded in Jerusalem in 1901 as a drug wholesaler, Teva grew into the world's largest maker of generic medicines. A debt-funded acquisition in 2016, falling US generic prices and opioid lawsuits then nearly broke it. Richard Francis became chief executive in 2023 with a plan to shift towards branded medicines: Austedo for movement disorders, Ajovy for migraine and Uzedy for schizophrenia now provide most of the growth, alongside biosimilars.
Investment case
- Branded products are growing quickly and carry much higher margins than generics.
- Debt has fallen steadily and credit ratings are improving.
- A pipeline of biosimilars and new branded drugs.
Key risks
- Austedo is subject to US government price negotiation.
- Generics remain a low-margin, competitive business.
- Debt is still large relative to equity.
Revenue by segment
| Generic medicines | 52% |
| Innovative medicines | 30% |
| Ingredients and other | 18% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $17.4B | $2.3B |
| Year 2 | $17.9B | $2.4B |
| Year 3 | $18.4B | $2.5B |
| Year 4 | $18.9B | $2.6B |
| Year 5 | $19.4B | $2.8B |
What the street says
A recovery story that has largely played out; now judged on its branded pipeline.
Comparable companies: BIIB · IQV · GEHC · BDX · TAK · BSX · ELV · GSK
Open the interactive model, price chart and sensitivity grid →